CENBF

$0.00+$0.00 (+0.00%)prev close

Compare

Held by

portfolios on TandT

Bookmarked by

users

Avg position size

—

of holders' portfolios

13F filers

institutions

52-week range

$0.00 – $0.00

50% from low

Exchange

OTC Link

Borrow rate

0.25%

Easy to borrow

Price (6 mo)

Loading chart…

Change$-0.21

Valuation

Financials

Loading chart…

Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.

	2015	2016	2017	2018	2019	2020	2021	2022
Revenue	$0	$2.3K	$0	$0	$0	$0	$626.9K	$987.1K
Cost of revenue	$0	$142.9K	$0	$4.4M	$2.6M	$435.5K	$0	$489.1K
Gross profit	$0	−$141.0K	−$11.6M	−$4.4M	−$2.6M	−$435.5K	$626.9K	$498.0K
Gross margin	—	-6075.0%	—	—	—	—	100.0%	50.5%
R&D	$0	$0	$32.0K	$41.0K	$0	$0	$0	$0
Operating income	−$1.0M	−$1.2M	−$11.6M	−$3.1M	−$2.6M	−$2.2M	−$19.0M	−$1.3M
EBITDA	−$1.0M	−$6.5M	−$11.6M	−$4.2M	−$1.9M	$18.4M	−$17.6M	−$773.0K
Net income	−$2.4M	−$7.6M	−$14.1M	−$7.5M	−$5.7M	$14.2M	−$18.9M	−$1.5M
Net margin	—	-326669.5%	—	—	—	—	-3015.6%	-153.5%
EPS (diluted)	-0.34	-0.92	-1.68	-0.30	-0.35	0.45	-0.45	-0.02

Annual figures · source: Financial Modeling Prep

DCF fair valuemodel estimate

Intrinsic value

$0.78

Price

$0.00

Implied upside

+780022%

Peer comparison

Symbol	Price	Today	Mkt cap	P/E
CENBFCEN Biotech, Inc.	$0.00	+0.00%	$6526	—
BLMSBloomios, Inc.	$0.00	+0.00%	$6447	—
DNAGDNAPrint Genomics, Inc.	$0.00	+0.00%	$12892	—
MJNEMJ Holdings, Inc.	$0.00	+0.00%	$11654	—
SAGDSouth American Gold Corp.	$0.00	+0.00%

CEN BIOTECH INC ORD

Held by traders on TradeandTell

No one on the platform currently holds CENBF.

Super investors & insiders

Institutions holding (13F)

No tracked institution reports a position in CENBF as of their last filing.

Insider activity (SEC Form 4)

No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.

Insider activity (SEC Form 4)

Recent trades on TradeandTell

No one on the platform has traded CENBF yet.

$CENBF chatter on StockTwits

xinhaoc@luiselenBullishMay 15
$WIMI WITH ER NEXT MONDAY AND THIS PT THIS IS DUE A HUGE MOVE 🚨🚨🚨 WIMI IS EXPECTED TO HAVE HIGH EARNINGS FOR Q2. Added 5k here. $EVKG $GSIT $CENBF
View on StockTwits ↗
FlashAlert_me@flaApr 12
$CENBF [15s. delayed] filed form 15-12G on April 12, 16:02:01 https://s.flashalert.me/OJuat
View on StockTwits ↗
FlashAlert_me@flaApr 6
$CENBF [15s. delayed] filed form NT 10-K on April 06, 13:56:41 https://s.flashalert.me/mxYKRn
View on StockTwits ↗
FlashAlert_me@flaMar 29
$CENBF [15s. delayed] filed form 8-K on March 29, 16:06:06 https://s.flashalert.me/TkeDd
View on StockTwits ↗
PennyScamz@PennyScamzBullishFeb 23
$CENBF +164.67% low floater!
View on StockTwits ↗
PennyScamz@PennyScamzBullishFeb 22
$CENBF heading for a breakout soon!
View on StockTwits ↗
Blaze ING Stocks@BlazingStocksFeb 16
$CENBF News November 08, 2022 CEN Biotech Inc. Announces Word Presto Partner Program https://finance.yahoo.com/news/cen-biotech-inc-announces-word-133000008.html
View on StockTwits ↗
Blaze ING Stocks@BlazingStocksFeb 15
$CENBF News September 16, 2022 CEN Biotech Inc. Announces the Pending Launch of WordPresto https://www.einpresswire.com/article/591282607/cen-biotech-inc-announces-the-pending-launch-of-wordpresto
View on StockTwits ↗
👑 STOCK DAILY NEWS 👑@STOCK_DAILY_NEWSFeb 14
$CENBF #FrontPageStocks #CENBF has announced the planned launch of its newest technology product, WordPresto (www.wordpresto.com) was set for September 28, 2022. This launch event was also set up to be broadcast on both Facebook Live and YouTube live to highlight WordPresto’s capabilities aiming to revolutionize the web design market and to address the needs of scalable and affordable web design. https://frontpagestocks.com/cen-biotech-inc-otcqb-cenbf/
View on StockTwits ↗
Blaze ING Stocks@BlazingStocksFeb 14
$CENBF Benzinga Article October 12, 2022 Profitable Custom AI User-Friendly Website Development Services Plus Other Digital Media Technologies Now Being Made Available for a Wide Range of Client Applications https://www.benzinga.com/pressreleases/22/10/ab29229256/profitable-custom-ai-user-friendly-website-development-services-plus-other-digital-media-technolo
View on StockTwits ↗
Master Jedijazz@UltimateTrader_22BullishFeb 13
$CENBF has fully embraced the power of Artificial Intelligence and intends to design a series of products and services that utilize A.I. technologies to make everyday life easier, more efficient informative, and entertaining. #AI #OTCQB $GNS https://www.benzinga.com/pressreleases/22/10/ab29229256/profitable-custom-ai-user-friendly-website-development-services-plus-other-digital-media-technolo
View on StockTwits ↗
Blaze ING Stocks@BlazingStocksFeb 13
$CENBF has an attractive share structure with only about 62 million shares outstanding making this a lean stock that can climb easily as buying pressure comes in. In conjunction with its new business plans, CENBF has begun the process of seeking to complete a company name change that will be appropriate to its forward-looking objectives. CENBF management intends to focus mainly on the digital media and technology space with the launch of technology products, beginning at this time.
View on StockTwits ↗
👑 STOCK DAILY NEWS 👑@STOCK_DAILY_NEWSFeb 13
#FrontPageStocks CEN Biotech, Inc. #OTCQB - $CENBF Custom AI User-Friendly Website Development Services Plus Other Digital Media Technologies Now Being Made Available for a Wide Range of Client Applications ReadMore:https://frontpagestocks.com/cen-biotech-inc-otcqb-cenbf/ Visit:https://coeptistx.com/
View on StockTwits ↗
Blaze ING Stocks@BlazingStocksFeb 13
$CENBF News November 08, 2022 CEN Biotech Inc. Announces Word Presto Partner Program https://finance.yahoo.com/news/cen-biotech-inc-announces-word-133000008.html
View on StockTwits ↗
Blaze ING Stocks@BlazingStocksFeb 10
$CENBF News November 08, 2022 CEN Biotech Inc. Announces Word Presto Partner Program https://finance.yahoo.com/news/cen-biotech-inc-announces-word-133000008.html
View on StockTwits ↗

Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.